Exponent CEO Catherine Corrigan sold 1,737 shares at $62.78 via a 10b5-1 plan after exercising options. The stock underperformed the S&P 500 by 31.6 points over the past year.
Alpha Score of 43 reflects weak overall profile with moderate momentum, weak value, weak quality. Based on 3 of 4 signals — score is capped at 90 until remaining data ingests.
Exponent CEO Catherine Corrigan sold 1,737 shares at $62.78 on July 15, a transaction disclosed in a July 17 SEC filing. The sale was conducted under a 10b5-1 trading plan and followed the exercise of options for 2,379 shares at a $29.05 strike price. A portion of the proceeds went to cover the exercise cost and taxes, the filing showed.
Corrigan still holds a multimillion-dollar stake in the consulting firm. The structured nature of the sale – set in advance via the trading plan – suggests it was not a discretionary bet against the stock. Option exercises that coincide with share sales to cover taxes are routine for executives with large option grants.
The more material signal for investors may be Exponent's price action. The stock fell 11.7% over the 12 months through July 17, including dividends. The S&P 500 returned 19.9% over the same stretch – a 31.6-percentage-point underperformance.
Exponent provides engineering and scientific consulting services, largely for litigation support and product liability cases. The firm employs about 1,013 people and generates revenue through billable hours and project fees. Its two segments – engineering and other scientific, and environmental and health – serve Fortune 500 corporations and law firms, as well as government agencies and industrial manufacturers.
Insider selling, even when pre-planned, can weigh on sentiment when the stock is already under pressure. Exponent's revenue growth has been modest, and its reliance on litigation-driven demand introduces lumpiness. A sustained revenue miss or loss of a major client would compound the share-price weakness. A pickup in project activity or a cycle of insider buying would signal confidence.
Exponent reports second-quarter earnings on July 30. The filing did not disclose the timing of Corrigan's next scheduled trading window under the 10b5-1 plan.
Drafted by a large language model from the source reporting linked above, then screened by automated publishing checks. It is not read by a journalist before publication. Some articles cite our Alpha Score. Verify prices and figures against the original source. Educational coverage, not personalized advice.